WEST CONSHOHOCKEN, Pa. and OTTAWA--(BUSINESS WIRE)--Feb. 9, 2006--Zelos Therapeutics, Inc. announced today that the Company has completed enrollment in each of its Phase 2 clinical trials for Ostabolin-C(TM). Injectable Ostabolin-C is Zelos’ Phase 2 candidate for the treatment of osteoporosis. Zelos also has Ostabolin-C gel in Phase 2 for the topical treatment of psoriasis.
